- Home
- HIND vs AKTX Comparison
HIND vs AKTX Comparison
Compare HIND & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HIND | AKTX |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.9M | 11.5M |
| IPO Year | 2016 | 2014 |
Fundamental Metrics
Financial Performance| Metric | HIND | AKTX |
|---|---|---|
| Price | $2.30 | $0.14 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $2.53 |
| AVG Volume (30 Days) | 57.8K | ★ 347.5K |
| Earning Date | N/A | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.75 | $0.13 |
| 52 Week High | $12.87 | $1.58 |
Technical Indicators
Market Signals| Indicator | HIND | AKTX |
|---|---|---|
| Relative Strength Index (RSI) | 40.69 | 27.20 |
| Support Level | $2.02 | N/A |
| Resistance Level | $2.93 | $0.27 |
| Average True Range (ATR) | 0.19 | 0.03 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 28.87 | 4.30 |
Price Performance
Historical ComparisonAbout HIND Vyome Holdings Inc.
Vyome Holdings Inc is a reseach and development company. The Company operates in two segments, biotechnology and pharmaceutical products. The biotechnology segment comprises of operations around VT-1953, VT-1908, and VB-1953 programs that are in development, and the pharmaceutical segment comprises of antifungal products manufacturing and distribution.
About AKTX Akari Therapeutics plc ADS
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.